tsukushi, small leucine rich proteoglycanGenealiases: E2IG4 · LRRC54 · TSK
Q-omics provides the consensus-scored TSKU profile across patient tissues and cancer cell-line models. TSKU expression is associated with patient survival in 31 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TSKU is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TSKU RNA expression shows 18,423 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where TSKU shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSKU — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSKU survival associations across molecular data types. TSKU RNA expression shows survival associations in the most cancer types (31), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSKU RNA expression–survival associations across cancer types. High TSKU expression shows unfavorable associations in KIRC, ACC, LUAD and PAAD, but favorable associations in UVM and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TSKU RNA expression.
This table summarizes TSKU tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TSKU. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSKU shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, LUAD, LUSC and UCEC. The HNSC box plot shows higher TSKU RNA expression in tumor versus normal tissue (log2 FC = +1.255, t-test p < 0.001).
This table shows molecular features associated with TSKU in patient tissues and cancer cell lines. In patient samples, TSKU shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TSKU RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
